PA
CDAK

Parallel Advisors’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Parallel Advisors’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67
Closed -$1K – 3391
2021
Q3 		$1K Buy
67
+25
+60% +$447 ﹤0.01% 3011
2021
Q2 		$1K Buy
+42
New +$807 ﹤0.01% 2888

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parallel Advisors's CDAK Position: Q4 2021 in Review

Parallel Advisors sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q4 2021, closing a stake of 67 shares — an estimated $1K sold.

Parallel Advisors first reported a position in CDAK in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 51 funds tracked by Wall St. Rank hold CDAK as of Q4 2021.

  • Parallel Advisors reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Parallel Advisors sold 67 Codiak BioSciences, Inc. Common Stock shares in Q4 2021, an estimated $1K.
  • Parallel Advisors first reported a position in Codiak BioSciences, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Parallel Advisors's Codiak BioSciences, Inc. Common Stock position peaked at $1K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.